Foamix Pharmaceuticals Second Quarter 2015 Conference Call & Webcast Scheduled for Thursday, August 20

REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce second quarter 2015 financial results and host a conference call and webcast on Thursday, August 20, 2015.

Conference Call & Webcast
Thursday, August 20, 2015 @ 8:00am Eastern/5:00am Pacific
Domestic: 888-417-8533
International:  719-325-2329
Conference ID:  3726501
Webcast: http://public.viavid.com/player/index.php?id=115341
   
Replays available until September 3, 2015
Domestic:  877-870-5176
International:  858-384-5517
Passcode:  3726501

About Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals’ lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Ilan Hadar, CFO
         Foamix Pharmaceuticals Ltd.
         +972-8-9316233
         [email protected]
         
         U.S. Investor Relations
         Michael Rice
         LifeSci Advisors, LLC
         646-597-6979
         [email protected]

Foamix Pharmaceuticals Second Quarter 2015 Conference Call & Webcast Scheduled for Thursday, August 20

REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce second quarter 2015 financial results and host a conference call and webcast on Thursday, August 20, 2015.

Conference Call & Webcast
Thursday, August 20, 2015 @ 8:00am Eastern/5:00am Pacific
Domestic: 888-417-8533
International:  719-325-2329
Conference ID:  3726501
Webcast: http://public.viavid.com/player/index.php?id=115341
   
Replays available until September 3, 2015
Domestic:  877-870-5176
International:  858-384-5517
Passcode:  3726501

About Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals’ lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Ilan Hadar, CFO
         Foamix Pharmaceuticals Ltd.
         +972-8-9316233
         [email protected]
         
         U.S. Investor Relations
         Michael Rice
         LifeSci Advisors, LLC
         646-597-6979
         [email protected]